All In Biotech

Drug Trial Radar · NCT03861234

A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

Safety, Tolerability and Pharmacodynamics of Single Rising Intravitreal and Multiple Rising Intravitreal Doses of BI 836880 in Patients With wAMD (Open Label, Non-randomized, Uncontrolled).

Last checked: Nov 20, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

43

Actual

Start

Jun 27, 2019

Primary completion

Nov 1, 2023

Study completion Nov 1, 2023

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Mar 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study in people with an eye disease called wet age-related macular degeneration (wAMD). The purpose of the study is to find out how well different doses of a medicine called BI 836880 are tolerated. People can participate if they are at least 55 years old and if they have new blood vessels in their eyes despite treatment (anti-VEGF therapies). The study has 2 parts. In the first part, people get only 1 dose of BI 836880. This part takes 6 weeks. In the second part, people get 3 times the same dose of BI 836880. This part takes 6 months. BI 836880 is injected into the eye. During the entire study doctors regularly check the health of the participants.

Conditions

  • Wet Macular Degeneration

Interventions

  • BI 836880Drug

    Solution for Intravitreal (IVT) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SRD-part: Number of Participants With Ocular Dose Limiting Events (DLEs)Time frame: From drug administration until the end of trial (EOT) visit in the SRD part, up to 6 weeks.
  2. MRD-part: Number of Participants With Drug Related Adverse Events (AEs)Time frame: From first drug administration until the end of trial (EOT) visit in the MRD part, up to 24 weeks.

Locations

14 sites in 3 countries. Site status is shown where the registry gives one.

  • Associated Retina Consultants, Ltd.

    Phoenix, Arizona

  • New York Eye and Ear Infirmary of Mount Sinai

    New York, New York

  • Verum Research, LLC

    Eugene, Oregon

  • Erie Retina Research, LLC

    Erie, Pennsylvania

  • Retina Research Institute of Texas

    Abilene, Texas

  • Austin Clinical Research, LLC

    Austin, Texas

  • Retina Consultants of Texas

    Bellaire, Texas

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • Universitätsmedizin Göttingen, Georg-August-Universität

    Göttingen, Germany

  • Universitätsklinikum Ulm

    Ulm, Germany

  • Bristol Eye Hospital

    Bristol, United Kingdom

  • Royal Liverpool University Hospital

    Liverpool, United Kingdom

  • Moorfields Eye Hospital

    London, United Kingdom

  • Sunderland Eye Infirmary

    Sunderland, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.